Studies presented in this dissertation were conducted to gain more insight into the role of phospholipid asymmetry and amyloid-β (Aβ)-induced oxidative stress in brain of subjects with amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD). AD is a largely sporadic, age-associated neurodegenerative disorder clinically characterized by the vast, progressive loss of memory and cognition commonly in populations over the age of ~65 years, with the exception of those with familial AD, which develop AD symptoms as early as ~30 years-old. Neuropathologically, both AD and FAD can be characterized by synapse and neuronal cell loss in conjunction with accumulation of neurofibrillary tangles and senile plaques. Elevated levels of oxidative stress and damage to brain proteins, lipids, and nucleic acids are observed, as well. Likewise, aMCI, arguably the earliest form of AD, displays many of these same clinical and pathological characteristics, with a few exceptions (e.g., no dementia) and to a lesser extent. Studies in this dissertation focused on the contributions of oxidative stress to the exposure of phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, how and when PtdSer asymmetric collapse contributes to the progression of aMCI, AD, and FAD, and the role played by methionine-35 (Met-35) of Aβ in oxidative stress and damage, as measured in a transgenic mouse model of Aβ pathology. Normally, the PtdSer is sequestered to the cytosolic, inner-leaflet of the bilayer by the adenosine triphosphate (ATP)-dependent, membrane-bound translocase, flippase, which unidirectionally transports PtdSer inward against its concentration gradient. Oxidative stress-induced modification of flippase and/or PtdSer, however, leads to prolonged extracellular exposure of PtdSer on the outer membrane leaflet, a known signal for both early apoptosis and selective recognition and mononuclear phagocytosis of dying cells. Within the inferior parietal lobule (IPL) of subjects with aMCI and AD, a significant collapse in PtdSer asymmetry was found in association with increased levels of both pro- and anti-apoptotic proteins, Bax, caspase-3, and Bcl-2. Moreover, a significant collapse in PtdSer asymmetry was also found in whole brain of human double-mutant knock-in mouse models of Aβ pathology, together with significantly reduced Mg2+ATPase activity, representing flippase activity, and increased levels of pro-apoptotic caspase-3. Significant PtdSer externalization corresponded to the age at which significant soluble Aβ(1-42) deposition occurs in this particular mouse model (9 months), and not of plaque deposition (12 months), suggesting that elevated levels of Aβ(1-42), together with increasing oxidative stress and apoptosis, may contribute to altered PtdSer membrane localization. Also in this dissertation, transgenic mice carrying Swedish and Indiana mutations on the human amyloid precursor protein (APPSw,In) and APPSw,In mice carrying a Met35Leu mutation on Aβ were derived to investigate the role of Met-35 in Aβ(1-42)-induced oxidative stress in vivo. Oxidative stress analyses revealed that Aβ-induced oxidative stress requires the presence of Met-35, as all indices of oxidative damage (i.e., protein carbonylation, nitration, and protein-bound 4-hydroxy-2-trans-nonenal [HNE]) in brain of Met35Leu mice were completely prevented. Moreover, immunohistochemical analyses indicated that the Met35Leu mutation influences plaque formation, as a clear reduction in Aβ-immunoreactive plaques in Met35Leu mice was found in conjunction with a significant increase in microglial activation. In contrast, behavioral analyses suggested that spatial learning and memory was independent of Met-35 of Aβ, as Met35Leu mice demonstrated inferior water-maze performance compared to non-transgenic mice. Differential expression and redox proteomic analyses to pinpoint proteins significantly altered by the APPSw,In and Met35Leu mutations was performed, as well. Expression proteomics showed significant increases and decreases in APPSw,In and Met35Leu mouse brain, respectively, in proteins involved in cell signaling, detoxification, structure, metabolism, molecular chaperoning, protein degradation, mitochondrial function, etc. Redox proteomics found many of these same proteins to be oxidatively modified (i.e., protein carbonylation and nitration) in both APPSw,In and Met35Leu mouse brain, providing additional insights into the critical nature of Met-35 of Aβ for in vivo oxidative stress in a mammalian species brain, and strongly suggesting similar importance of Met-35 of Aβ(1-42) in brain of subjects with aMCI and AD. Taken together, studies presented in this dissertation demonstrate the role of oxidative stress-induced alteration of PtdSer asymmetry and Met-35 in Aβ-induced oxidative stress in aMCI, AD, and FAD brain.

Alzheimer s (DA) is a neurodegenerative disease evidenced by cognitive disorders and attention deficit and learning, and is the main cause of dementia in the elderly. The amyloid hypothesis posits that extracellular amyloid-β (Aβ) deposits are the fundamental etiological factor of the disease. However, the AD etiology has yet to be fully understood and common treatments remain largely non-efficacious. Caernorhabditis elegans transgenic strains expressing toxic Aβ has been employed as AD in vivo model in order to elucidate mechanisms and verifying the effectiveness of pharmacological compounds. The organoselenium compound tested in this study, Diphenyl-diselenide (PhSe)2, has shown efficacy in ameliorate several parametres in neurodegenerative disease models. In the present study, we analyzed the effects of (PhSe)2 chronic treatment on Aβ peptide-induced toxicity in C. elegans. This data shows that chronic exposure to (PhSe)2 attenuated oxidative stress induced by Aβ with concomitant recovery of associative learning memory in worms. In addition, (PhSe)2 decreased Aβ transgene expression, suppressing the Aβ peptide and down-regulating hsp-16.2 by reducing the need of this chaperone under Aβ toxicity. This observations suggest that (PhSe)2 plays an important role in protection against oxidative stress-induced toxicity, this representing a promising potential pharmaceutical modality by attenuating Aβ expression. / A Doença de Alzheimer (DA) é uma doença neurodegenerativa evidenciada por distúrbios cognitivos e déficit de atenção e aprendizagem, sendo a principal causa de demência em idosos. A Hipótese Amilóide postula o acúmulo de depósitos extracelulares do peptídio β-amilóide (Aβ) no cérebro como o principal fator da doença. Entretanto, sua etiologia ainda não está completamente elucidada e seu tratamento visa apenas a melhora dos sintomas. Cepas transgênicas do nematódeo Caernorhabditis elegans que expressam as espécies tóxicas Aβ, têm sido utilizadas como modelos in vivo de DA para elucidar mecanismos e verificar a eficácia de novas moleculas. O disseleneto de difenila ((PhSe)2), composto orgânico de selênio utilizado nesse estudo, tem demonstrado eficácia em melhorar diversos parâmetros em modelos de doenças neurodegenerativas. No presente estudo foram analisados os efeitos do tratamento crônico com (PhSe)2 na toxicidade induzida pela Aβ em C. elegans. Os resultados mostraram que a exposição crônica ao (PhSe)2 atenuou o estresse oxidativo induzido pela Aβ, além de recuperar a memória associativa no nematódeo. Além disso, o (PhSe)2 diminuiu a expressão do gene Aβ, levando a supressão do peptídio Aβ e reduzindo a expressão do gene hsp-16.2, por diminuir a necessidade desta chaperona frente a toxicidade Aβ. Estes dados sugerem que o (PhSe)2 desempenha um importante papel na proteção contra a toxicidade induzida por estresse oxidativo, além de representar um promissor agente farmacológico por atenuar a expressão do Aβ.

Amyloid PET imaging with [11C]PIB enabled detection of Aβ for the first time in vivo. However, [11C]PIB is a small molecule that binds only the insoluble Aβ plaque. Rather, the soluble Aβ aggregates are considered the cause of Alzheimer’s disease (AD). As such, a more sensitive and specific PET tracer is needed for tracking longitudinal AD pathology. Soluble Aβ aggregates likely interact with the metabotropic glutamate receptor 5 (mGluR5) to cause neurotoxic effects. However, with [11C]ABP688 PET we were unable to detect aberrant mGluR5 binding in AD mouse models, although we find elevated mGluR5 protein levels with immunoblotting. Antibodies are highly specific large molecules that can bind specifically to soluble Aβ aggregates, thus they can be a good marker for AD pathology. Unfortunately, due to their large size they cannot cross the blood-brain barrier (BBB). However, it is possible to shuttle antibodies into the brain by taking advantage of endogenous transporter systems on the BBB. By creating bispecific antibodies binding both to soluble Aβ aggregates and to the transferrin receptor (BBB target), we successfully transported the antibody into the brain and could visually detect soluble Aβ aggregates with PET. Recombinant expression further improved and optimized antibody design, creating smaller bispecific antibody-based constructs that had better pharmacokinetic properties allowing for earlier PET scanning (1 day instead of 3), and more sensitive signal. Lastly, using TCO-tetrazine click chemistry, we indirectly labeled our antibodies with fluorine-18, and could successfully perform PET already 11 h post-injection with a fluorine-18 labeled antibody.

De nombreuses protéines associées aux maladies neurodégénératives humaines sont intrinsèquement désordonnées. Ce sont des protéines qui sont dépourvues de structure tertiaire ou secondaire stable dans des conditions physiologiques. Plus précisément, les protéines intrinsèquement désordonnées (IDPs) subissent diverses changements conformationnels entre la pelote aléatoire, des conformations hélicoïdales et des structures en feuillet-β, ces deux dernières étant généralement impliquées dans la reconnaissance protéine-protéine. Parmi une vingtaine de peptides amyloïdogènes connus liés aux maladies dégénératives humaines, notre étude porte sur deux protéines désordonnées: le peptide Amyloïde-β (Aβ) associé à la maladie d'Alzheimer et l'Islet Amyloid Polypeptide (IAPP) impliqué dans le diabète de type II. Aβ possède deux alloformes courants de 40 et 42 résidus, tandis que IAPP est une hormone peptidique de 37 résidus. Les agrégats de Aβ sont toxiques pour les cellules du cerveau, tandis que la fibrillisation de IAPP affecte les cellules-β du pancréas. Le mécanisme d'agrégation de ces deux peptides reste encore mal connu, mais il a été proposé qu’en solution, ces peptides visitent différentes conformations, l'une d'entre elles étant riche en feuillets-β. Cela conduirait à l’oligomérisation de ces peptides, par le biais d’interactions feuillet-β / feuillet-β et, éventuellement, à la formation de fibrilles. Le but de notre étude est de mieux caractériser la dynamique conformationnelle de ces deux peptides, dans leur forme monomérique et oligomérique. Comprendre les premières étapes de leur agrégation est crucial pour le développement de nouvelles molécules thérapeutiques efficaces contre ces protéines amyloïdes. / Many proteins associated with human neurodegenerative diseases are intrinsically disordered. They are proteins which lack stable tertiary or secondary structure under physiological conditions. More specifically, intrinsically disordered proteins (IDPs) undergo various structural conversions between random coil, helical conformations and β-strand structures, these two latter being generally involved in protein-protein recognition. Among about twenty known amyloidogenic peptides related to human degenerative diseases, we focus our study on two disordered proteins: the Amyloid-β peptide (Aβ) associated to the Alzheimer’s disease and the Islet Amyloid Polypeptide (IAPP) involved in type II diabetes. Aβ has two common alloforms of 40 and 42 residues in length, meanwhile IAPP is a 37-residues peptide hormone. Aggregates of Aβ are toxic to the brain cells, meanwhile IAPP fibrillization affects the pancreatic β-cells. The aggregation mechanism of these two peptides is not known in detail, but it was proposed that in solution, these peptides visit various conformations, one of them being rich in β-strands. This would lead to peptide oligomerization, through β-strand / β-strand interactions and eventually to the fibril formation. The aim of our study is to provide insights into the conformational dynamics of these two peptides in monomeric and oligomeric forms. Understanding the early steps of their aggregation is crucial for the development of new effective therapeutic molecules against these amyloid proteins.De nombreuses protéines associées aux maladies neurodégénératives humaines sont intrinsèquement désordonnées. Ce sont des protéines qui sont dépourvues de structure tertiaire ou secondaire stable dans des conditions physiologiques. Plus précisément, les protéines intrinsèquement désordonnées (IDPs) subissent diverses changements conformationnels entre la pelote aléatoire, des conformations hélicoïdales et des structures en feuillet-β, ces deux dernières étant généralement impliquées dans la reconnaissance protéine-protéine. Parmi une vingtaine de peptides amyloïdogènes connus liés aux maladies dégénératives humaines, notre étude porte sur deux protéines désordonnées: le peptide Amyloïde-β (Aβ) associé à la maladie d'Alzheimer et l'Islet Amyloid Polypeptide (IAPP) impliqué dans le diabète de type II. Aβ possède deux alloformes courants de 40 et 42 résidus, tandis que IAPP est une hormone peptidique de 37 résidus. Les agrégats de Aβ sont toxiques pour les cellules du cerveau, tandis que la fibrillisation de IAPP affecte les cellules-β du pancréas. Le mécanisme d'agrégation de ces deux peptides reste encore mal connu, mais il a été proposé qu’en solution, ces peptides visitent différentes conformations, l'une d'entre elles étant riche en feuillets-β. Cela conduirait à l’oligomérisation de ces peptides, par le biais d’interactions feuillet-β / feuillet-β et, éventuellement, à la formation de fibrilles. Le but de notre étude est de mieux caractériser la dynamique conformationnelle de ces deux peptides, dans leur forme monomérique et oligomérique. Comprendre les premières étapes de leur agrégation est crucial pour le développement de nouvelles molécules thérapeutiques efficaces contre ces protéines amyloïdes.

Introduktion: Alzheimers sjukdom är en neurodegenerativ sjukdom som orsakas av ansamling av amyloid-β (Aβ) i hjärnan. Prevalensen av Alzheimers sjukdom ökar, och symtom inkluderar minnesförlust, ångest, depression, förvirring, nedsatt omdöme och desorientering. Ålder och genetiska varianter är två riskfaktorer för att utveckla Alzheimers sjukdom. Det finns två modeller som förklarar hur sjukdomen kan uppstå, 1) den amyloida hypotesen som beskriver hur deposition av Aβ leder till ökad aggregation av proteinet tau vilket orsakar celldöd och neurodegeneration, och 2) den kolinerga hypotesen vilken beskriver att Aβ-plack minskar produktionen av acetylkolin vilket leder minskad aktivitet i kolinerga nerver. Det är främst entorhinala cortex och hippocampus som drabbas. Diagnostisering görs genom medicinska och neurologiska undersökningar och genom standardiserade test/instrument. I dagläget kan symtom av Alzheimers sjukdom behandlas med acetylkolinesterasinhibitorer och memantin. Ett annat behandlingssätt är att använda monoklonala antikroppar som riktats mot Aβ för att minska belastningen av Aβ i hjärnan. För att bedöma effekt av sådana läkemedel används bedömningsmetoder baserade på kognitiva och funktionella tester.  Syfte: Syftet med detta arbete var att undersöka effektivitet och säkerhet av anti-Aβ antikroppar för behandling av Alzheimers sjukdom, vilket gjordes genom att analysera kognitiv förmåga, biomarkörer och biverkningar.  Metod: Detta arbete är en litteraturstudie som baserades på fem läkemedelsstudier vilka erhölls från databasen PubMed. Sökord som användes vid litteratursökning var ”aducanumab”, ”lecanemab”, ”donanemab”, ”crenezumab” och ”bapineuzumab”.  Resultat: Hög dos aducanumab i studien EMERGE och lecanemab visade statistiskt signifikant förändring på alla utfallsvariabler, och analys av biomarkörer visade minskad amyloid-belastning i hjärnan. Donanemab visade statistiskt signifikant skillnad på den primära utfallsvariabeln och på analys av biomarkörer, men resultat på sekundära utfallsvariabler var inte statistiskt signifikanta. Crenezumab visade endast statistiskt signifikant förändring på den primära utfallsvariabeln i CREAD2. Bapineuzumab visade ingen statistiskt signifikant skillnad på någon utfallsvariabel eller på förändringar i biomarkörer. De resultat som var statistiskt signifikanta indikerade minskad kognitiv försämring hos patienterna. ARIA var en vanlig biverkning hos alla läkemedel utom crenezumab, men förekomsten av ARIA var i de flesta fall mild till måttlig. Andra vanliga biverkningar inkluderade infusionsrelaterade reaktioner, huvudvärk och fall.  Slutsats: Baserat på resultaten från detta arbete dras slutsatsen att aducanumab, lecanemab och donanemab var de läkemedel med högst effektivitet. Framtiden ser mest lovande ut för aducanumab och lecanemab med anledning av positiva resultat på primära och sekundära utfallsvariabler och biomarkörer samt FDAs godkännande av läkemedlen i USA. Förekomsten av ARIA påverkar säkerheten av läkemedlen och därför behöver fler studier genomföras för att undersöka deras säkerhet ytterligare. / Background: Alzheimer’s disease is a neurodegenerative disease that is caused by accumulation of amyloid-β (Aβ) in the brain. The prevalence of Alzheimer’s disease is increasing, and symptoms of the disease include memory loss, anxiety, depression, confusion, impaired judgment and disorientation. Age and genetic variants are the two main risk factors for developing Alzheimer’s disease. There are two models which describe the development of the disease, 1) the amyloid hypothesis which describes how the deposition of Aβ leads to increased aggregation of the protein tau, which causes neuronal cell death and neurodegeneration, and 2) the cholinergic hypothesis which describes that Aβ plaques decrease the production of acetylcholine, this causes less activity in cholinergic neurons. The two areas in the brain which are mainly affected by neurodegeneration are the entorhinal cortex and the hippocampus. Diagnosing Alzheimer’s disease is done by medicinal and neurological assessments and by using standardized tests/instruments. Currently only symptomatic treatments for Alzheimer’s disease are available; acetylcholine esterase inhibitors and memantine. Another treatment method is using monoclonal antibodies against Aβ to decrease the Aβ load in the brain. To assess the effectiveness of these drugs assessment methods based on cognitive and functional tests can be used.  Aim: This study aimed to analyse the efficacy and safety of anti-Aβ antibodies as a treatment for Alzheimer’s disease, which was done by analysing cognitive ability, biomarkers and adverse events.  Method: This literature study was based on 5 clinical randomized controlled trials which were obtained from the PubMed database. Keywords that were used in the searches were “aducanumab”, “lecanemab”, “donanemab”, “crenezumab” and “bapineuzumab”.  Results: High-dose aducanumab in the study EMERGE and lecanemab showed statistically significant differences on all endpoints, and analysis of biomarkers showed a decrease in amyloid load in the brain. Donanemab showed statistically significant differences on the primary endpoint and analysis of biomarkers but results on secondary endpoints were not statistically significant. Crenezumab only showed statistically significant change on the primary endpoint in CREAD2. Bapineuzumab did not show statistically significant differences on any endpoint or on changes in levels of biomarkers. Statistically significant results on primary and secondary endpoints indicated decreased cognitive impairment among the patients. ARIA was a common adverse event in all drugs, with exception of crenezumab, but the occurrence of ARIA was in most cases mild to moderate. Other common adverse events were infusion-related reactions, headaches and falls.  Conclusion: With consideration of the results of this paper a conclusion can be drawn that aducanumab, lecanemab and donanemab have been shown to be effective on primary endpoints and analysis of biomarkers. The drugs that seem the most promising are aducanumab and lecanemab, mainly because they showed efficacy on both primary and secondary endpoints, and biomarkers and because of the FDA’s recent approval of both drugs in the US. The occurrence of ARIA is something that affects the safety of these drugs and because of this more studies are needed to further assess their safety.

All over the world, societies are facing rapidly aging populations combined with a growing number of patients suffering from Alzheimer’s disease (AD). One focus in pharmaceutical research to address this issue is on the reduction of the longer amyloid-β (Aβ) fragments in the brain by modulation of γ-secretase, a membrane-bound protease. R-Flurbiprofen (tarenflurbil) was studied in this regard but failed to show significant improvement in AD patients in a phase 3 clinical trial. This was mainly attributed to its low ability to cross the blood–brain barrier (BBB). Here, we present the synthesis and in vitro evaluation of a racemic meta-carborane analogue of flurbiprofen. By introducing the carborane moiety, the hydrophobicity could be shifted into a more favourable range for the penetration of the blood–brain barrier, evident by a logD7.4 value of 2.0. Furthermore, our analogue retained γ-secretase modulator activity in comparison to racemic flurbiprofen in a cell-based assay. These findings demonstrate the potential of carboranes as phenyl mimetics also in AD research.

No description available.

Alzheimer’s disease is an incurable neurodegenerative disorder linked to the amyloid β (Aβ) peptide, a 38-43 residue peptide. The detailed molecular disease mechanism(s) is (are) unknown, but oligomeric Aβ structures are proposed to be involved. In common for the papers in this thesis is interactions; interactions between Aβ(1-40) and selected molecules and metal ions. The purpose has been to find out more about the structural states that Aβ can adopt, in particular the β-sheet state, which probably is linked to the oligomeric structures. The methods used have been nuclear magnetic resonance (NMR), circular dichroism (CD) and fluorescence spectroscopy using Thioflavin T (ThT). Upon addition of SDS/LiDS detergent or Congo red (CR) to Aβ(1-40), the initial random coil/PII-helix state was transformed into β-sheet and, in the case of detergent, a final α-helical state. In contrast to SDS/LiDS and CR, the dimeric Affibody molecule locks monomeric Aβ(1-40) in a β-hairpin state. It was found that by truncating the flexible N-terminal end of the Affibody molecule its affinity to Aβ was improved. The aggregation of Aβ(1-40) was further studied in the presence of a β-cyclodextrin dimer by a kinetic assay using ThT. Although having a weak dissociation constant in the millimolar range, the β-cyclodextrin dimer modified the aggregation pathways of Aβ. Finally Aβ(1-40) was studied in presence of Cu2+ and Zn2+ at physiological and low pH. Cu2+ was observed to maintain its specific binding to Aβ when decreasing the pH to 5.5 while Zn2+ behaved differently. This could be of importance in the Alzheimer’s disease brain in which the environment can become acidic due to inflammation.        In conclusion the results show that Aβ(1-40) is very sensitive to its environment, responding by adopting different conformations and aggregating in aqueous solutions. The β-sheet state is induced by varying molecules with different properties, properties that govern the final Aβ state. / At the time of the doctoral defense, the following papers were unpublished and had a status as follows: Paper 4: Manuscript. Paper 5: Manuscript.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Memory is considered to be a process that has several stages, including acquisition, consolidation and retrieval. Memory impairment occurs when important synapses are modified. Alzheimer s disease (DA) is the most common cause of dementia. DA is characterized by cognitive damage, accumulation of the pathogenic amyloid-β (Aβ) peptide, and cholinergic dysfunction. Moreover, oxidative stress is associated with DA. Therapies used for dementia are still palliative rather than curative. Consequently, new therapies are urgently required. Biological effects of tellurium compounds have been studied, leading to a set of interesting and promising applications. Accordingly, 2-phenylethinyl-butyltellurium (PEBT), an organotellurium compound, has been reported as antioxidant. The purpose of this study was to characterize PEBT as a promising alternative for memory improvement and prevention of cognitive deficits, using experimental models of DA in mice. Initially, the present study was conducted to evaluate the effect of a single oral administration (p.o.) of PEBT at a dose of 10 mg/kg on memory, employing the step-down inhibitory avoidance task. PEBT administered 1 h before training, immediately after training or 1 h before the test session of the step-down inhibitory avoidance task increased the step-down latency time in comparison to the control mice, improving acquisition, consolidation, and retrieval of memory, respectively. The glutamate uptake, but not glutamate release, by cerebral cortex and hippocampal slices of mice was inhibited after 1 h of treatment with PEBT. After 24 h of PEBT exposure, the inhibition of cerebral cortex glutamate uptake disappeared. The improvement of memory by PEBT seems most likely to be mediated through an interaction with the amino acid transporters of the glutamatergic system. Thereafter, a subchronic PEBT treatment (1 mg/kg, p.o., for 10 days) after injection of Aβ(25-35) (3 nmol/3 μl/per site, intracerebroventricular) reversed Aβ-induced learning and memory deficits in the Morris water maze and step-down inhibitory avoidance tasks. In addition, PEBT (10 mg/kg, p.o.), administered 30 min before scopolamine (1 mg/kg, intraperitoneal), ameliorated memory deficit induced by this amnesic agent in the Morris water maze. Further, scopolamine was given 30 min before training and test or immediately post-training of step-down inhibitory avoidance task, inducing damage on acquisition, retrieval, and consolidation of memory, respectively. PEBT, administered 30 min before scopolamine, improved consolidation and retrieval stages, but not acquisition. General locomotor and exploratory activities, evaluated in the open-field test, were similar in all mice. Finally, the antiapoptotic effect of PEBT was evaluated. Human retinal pigment epithelial cells (ARPE-19 cell line) were exposed to in vitro oxidative stress by 10 ng/ml tumor necrosis factor-α and 600 μM H2O2. One hour PEBT incubation at concentrations of 7.5 and 10 μM attenuated the apoptosis induced by oxidative stress. This effect lasted up to 6 hours after oxidative stress induction. PEBT (5 and 10 μM) inhibited oxidative stress-induced poly (ADP-ribose) polymerase (PARP) cleavage and restored extracellular-signal-related kinase (ERK) phosphorylation decreased by oxidative stress. The protective mechanism exerted by PEBT against oxidative stress may involve PARP cleavage, regulation of ERK pathway, as well as its known antioxidant properties. In conclusion, the finds of the present thesis point out the ameliorative effect of PEBT on memory stages (acquisition, consolidation and retrieval). Likewise, PEBT improved memory impairment in mice. These effects seem to be due to strengthen the physiological glutamatergic tonus by PEBT and the antiapoptotic effect of PEBT. Therefore, PEBT could be considered a candidate for the prevention of memory deficits such as those observed in DA. / memória inclui pelo menos três tipos de processamento relacionados entre si: aquisição, consolidação e evocação. A memória é afetada quando as sinapses encarregadas de fazer ou evocar memórias encontram-se alteradas. A doença de Alzheimer (DA) é a causa mais comum de demência. A DA é caracterizada por danos cognitivos, acúmulo de peptídeo β-amiloide (Aβ) e disfunção colinérgica. Além disso, o estresse oxidativo está associado à DA. Uma vez que ainda não há cura para a DA e as terapias atuais são apenas paliativas, torna-se importante a busca de novos compostos para melhorar danos cognitivos. Com o estudo dos efeitos biológicos de compostos de telúrio, muitas aplicações estão sendo descobertas. Neste sentido, o composto orgânico de telúrio 2-feniletinil-butiltelúrio (PEBT) apresenta efeito antioxidante. O objetivo deste estudo foi caracterizar o PEBT como uma alternativa promissora para a melhora e prevenção de danos cognitivos, usando modelos experimentais da DA em camundongos. Primeiramente, avaliou-se o efeito de uma única dose oral (p.o) de PEBT (10 mg/kg) na memória, utilizando a tarefa da esquiva inibitória. O tratamento com PEBT 1 h antes do treino, imediatamente após o treino ou 1 h antes do teste da esquiva inibitória aumentou a latência comparada com os animais controles, melhorando a aquisição, consolidação e evocação da memória, respectivamente. A captação de glutamato, mas não a liberação deste neurotrasmissor, foi inibida em córtex e hipocampo de camundongos após 1 h de tratamento com PEBT. Após 24 h, a inibição da captação de glutamato no córtex não foi mais evidenciada. A melhora da memória causada pelo PEBT parece ser mediada através da interação com os transportadores de glutamato. Além disso, o tratamento subcrônico com PEBT (1 mg/kg, p.o., por 10 dias) após a injeção de Aβ(25-35) (3 nmol/3 μl/per site, intracerebroventricular) reverteu o prejuízo no aprendizado e na memória causados por Aβ nas tarefas do labirinto aquático de Morris e na esquiva inibitória. O PEBT (10 mg/kg, p.o.), adminstrado 30 min antes da escopolamina (1 mg/kg, intraperitoneal), também protegeu do dano de memória causado por este agente anticolinérgico no labirinto aquático de Morris. Quando a escopolamina foi administrada 30 min antes do treino ou teste, ou imediatamente após o treino da esquiva inibitória houve dano na aquisição, evocação e consolidação da memória, respectivamente. O PEBT, administrado 30 min antes da escopolamina, protegeu do dano na consolidação e evocação da memória, mas não na aquisição. Não houve diferença nas atividades locomotora e exploratória dos animais tratados com o PEBT no teste do campo aberto. Finalmente, o efeito antiapoptótico do PEBT foi avaliado. Células do epitélio pigmentado da retina humana (linhagem ARPE-19) foram expostas ao estresse oxidativo induzido pelo fator de necrose tumoral-α (10 ng/ml) e H2O2 (600 μM). O PEBT (7.5 e 10 μM), quando pré-incubado por 1 h, protegeu contra a apoptose induzida pelo estresse oxidativo e este efeito permaneceu até 6 h após a indução. O PEBT (5 e 10 μM) inibiu a clivagem da poli(ADP-ribose) polimerase (PARP) induzida por estresse oxidativo e, também, restaurou a fosforilação da quinase regulada por sinal extracelular (ERK). O efeito protetor do PEBT contra o estresse oxidativo parece envolver a clivagem da PARP e a regulação da fosforilaçao de ERK, além de sua atividade antioxidante. Nesse sentido, os resultados apresentados nesta tese destacam o efeito do PEBT na melhora das três fases da memória, bem como em modelos de dano cognitivos em camundongos. Estes resultados parecem estar relacionados ao aumento do tônus glutamatérgico causado pelo PEBT e seu efeito antiapoptótico. Assim sendo, estes dados sugerem que o PEBT poderá, futuramente, ser considerado candidato para a prevenção de danos de memória, como aqueles observados na DA.

アルツハイマー病の原因物質とされるAβの前駆体C99にはGXXXGモチーフ(以下モチーフ)が存在し、二量体形成に関与してAβ産生に影響を及ぼすとされる。そこでアミノ酸置換によりモチーフのないC99を調製し、その二量体形成とAβ産生への影響を検討した。その結果、モチーフは二量体形成には必要でないこと、Aβ産生を担う酵素の切断を制御する可能性が示された。以上より、モチーフが元来言われていた二量体形成よりも、Aβ産生に強く影響を及ぼすことを示唆している。 / Substitutions in GXXXG motifs did not significantly alter C99 dimerization, decreased the production of long Aβ species and increased short Aβ species, and decreased the ratios of precursor/product. In conclusion, my data indicate that GXXXG motifs of C99 are not crucial for the formation of C99 dimers. My findings might be useful for a development of new ways of therapeutic interventions. Because the amino acid substitutions in GXXXG motifs reduced the levels of amyloidogenic Aβ production, drugs targeted to GXXXG motifs would reduce the production of substances of great interest in the field of Alzheimer neuropathology, thereby inhibiting the formation of amyloid plaques. / 博士(理学) / Doctor of Philosophy in Science / 同志社大学 / Doshisha University